First Subject Enrollment in GT20029 China Phase 2 Trial for Acne
Suzhou, June 17, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Company has completed the first subject enrollment in the phase II clinical trial in China of its in-house developed androgen receptor proteolysis targeting chimera (“PROTAC”) compound GT20029 for the treatment of acne. Developed by the Company’s in-house PROTAC platform, GT20029 is the first topical PROTAC compound which has entered the phase II clinical stage worldwide. The Phase II Clinical Trial is a multi-center, randomized, double-blind, placebo-controlled study, which is designed to evaluate the efficacy, safety and pharmacokinetics of GT20029 for the treatment of acne through the adoption of GT20029 0.5% once-a-day (“QD”) and 1% QD as the drug-related dosage. The Pha
2023年第46届圣安东尼奥乳腺癌研讨会(SABCS 2023)于当地时间2023年12月5日至9日在美国圣安东尼奥召开。作为乳腺癌领域规模最大、最具影响力的国际性会议,超百项来自中国临床专家及创新药企的重磅临床研究精彩亮相本届SABCS。其中,开拓药业普克鲁胺联合内分泌药物(ETs)治疗转移性乳腺癌(mBC)的中国Ic期临床研究成果被选为亮点壁报展示(Poster Spotlight Presentation),由北京大学肿瘤医院李惠平教授在会上予以公布。 该项由李惠平教授担任主要研究者(leading PI)的临床研究结果显示,普克鲁胺联合氟维司群治疗转移性乳腺癌展现出令人鼓舞的抗肿瘤活性和良好的安全性。 亮点壁报展示 英文标题:Pruxelutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study 中文标题:普克鲁胺联合内分泌药物治疗HR+/HER2-/AR+转移性乳腺癌:一项Ic期临床研究 演讲者:李惠平(北京大学肿瘤医院) 展示时间:12月7日5:30 pm - 6:30 pm(当地时间) 展示形式:亮点壁报展示(Poster Spotlight Presentation) 展示编号:PS15-07 研究背景 普克鲁胺是开拓药业自主研发的一款选择性高亲和力非甾体雄激素受体(AR)拮抗剂。在Ia期和Ib期临床研究中,约25%的多线治疗失败后的mBC患者接受普克鲁胺治疗后出现了临床获益,且安全性良好。 这项多中心、开放标签、单臂Ic期临床研究(CTR20191063)旨在评估普克鲁胺联合内分泌治疗AR+/HR+/HER2- mBC患者的安全性、有效性和药代动力学特征,并探索潜在的生物标志物。 研究方法 该研究